Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H107e + CAF10b (Statens Serum Institut)
- Development stage
- Unknown
- Lead developer
- Statens Serum Institut
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
H107e + CAF10b is a next-generation subunit vaccine candidate for the prevention of tuberculosis (TB), developed by Statens Serum Institut. The vaccine consists of two components: - H107e, which is a recombinant protein containing eight Mycobacterium tuberculosis (Mtb)-specific antigens designed to elicit robust T cell responses. - CAF10b, a novel liposomal adjuvant incorporating a TLR9 agonist and optimized to induce strong Th1 and Th17 immune responses. The combination aims to complement or enhance the protective effect of BCG vaccination by generating novel T cell immunity against Mtb-specific antigens. Preclinical studies have shown that co-administration with BCG can further increase protection in previously BCG-primed animals. The vaccine is currently being evaluated in first-in-human phase 1 clinical trials for safety and immunogenicity in adults, including both people with and without Mtb infection[2][5][8]. The primary route of administration is intramuscular injection.
- Other names
- H107e + CAF®10b
02
Targets
CLEC4E (Macrophage-inducible C-type lectin receptor)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on H107e + CAF10b (Statens Serum Institut).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H107e + CAF10b (Statens Serum Institut).